New Perspectives on the Treatment of Panic and Phobic Disorders

  • Charlotte M. Zitrin


The treatment of panic and phobic disorders continues to be a challenging and sometimes difficult task. The recent National Institute of Mental Health collaborative epidemiological study found these disorders to be far more common than was previously believed. Indeed, phobias appear to be the most prevalent of all mental disorders in women. In men, the most prevalent is alcohol abuse or dependence. (Robins et al., 1984; Myers et al., 1984).


Panic Disorder Panic Attack Mitral Valve Prolapse Phobic Disorder Independent Evaluator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Capstick, N., & Rooke, K.C. (1974). A comparative trial of imipramine with phenelzine and chlorpromazine in the treatment of phobia. Journal of Internal Medicine Research, 2, 293–297.Google Scholar
  2. Crowe, R.R., Noyes, R., Pauls, D.L., & Slymen, D. (1983). A family study of panic disorder. Archives of General Psychiatry, 40, 1065–1069.PubMedCrossRefGoogle Scholar
  3. Garakani, H., Zitrin, C.M., & Klein, D.F. (1984). Treatment of panic disorder with imipramine alone. American Journal of Psychiatry, 141, 446–448.PubMedGoogle Scholar
  4. Harris, E.L., Noyes, R. Jr., Crowe, R.R., & Chaudhry, D.R. (1983). Family study of agoraphobic. Archives of General Psychiatry, 40, 1061–1064.PubMedCrossRefGoogle Scholar
  5. Kantor, J.S., Zitrin, C.M., & Zeldis, S.M. (1980). Mitral valve prolapse syndrome in agoraphobic patients. American Journal of Psychiatry, 137, 467–469.PubMedGoogle Scholar
  6. Kelly, D., Guirguis, W., Frommer, E., Mitchell-Heggs, N., & Sargent, W. (1970). Treatment of phobic states with antidepressants. British Journal of Psychiatry, 116, 387–398.PubMedCrossRefGoogle Scholar
  7. Klein, D.F. (1964). Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.PubMedCrossRefGoogle Scholar
  8. Klein, D.F. (1967). Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry, 16, 118–126.PubMedCrossRefGoogle Scholar
  9. Klein, D.F., Zitrin, C.M., Woerner, M.C., & Ross, D. (1983). Treatment of phobias. II. Behavior therapy and supportive psychotherapy: Are there any specific ingredients? Archives of General Psychiatry, 40, 139–145.PubMedCrossRefGoogle Scholar
  10. Lindemann, C.G., Zitrin, C.M., & Klein, D.F. (1984). Thyroid dysfunction in phobic patients. Psychosomatics, 25, 603–606.PubMedCrossRefGoogle Scholar
  11. Lipsedge, M.S., Hajioff, J., Huggins, P., Napier, L., Pearce, J., Pike, D., & Rich, M. (1973). The management of severe agoraphobia: A comparison of iproniazid and systematic desensitization. Psychopharmacologia, 32, 67–80.PubMedCrossRefGoogle Scholar
  12. Marks, I.M., Gray, S., Cohen, D., Hill, R., Mawson, D., Ramm, E., & Stern, R.S. (1983). Imipramine and brief therapist — aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry, 40, 153–162.PubMedCrossRefGoogle Scholar
  13. Mavissakalian, M., & Perei, J. (1985). Imipramine in the treatment of agoraphobia: Dose-response relationships. American Journal of Psychiatry, 142, 1032–1036.PubMedGoogle Scholar
  14. McNair, D.M., & Kahn, R.J. (1981). Imipramine compared with a benzodiazepine for agoraphobia. In D.F. Klein and J. Rabkin (Eds.), Anxiety: New research and changing concepts. New York: Raven Press.Google Scholar
  15. Myers, J.K., Weissman, M.M., Tischler, G.L., Holzer, C.G., III, Leaf, P.J., Orvaschel, H., Anthony, J.C., Boyd, J.H., Burke, J.D. Jr., Kramer, M., & Stoltzman, R. (1984). Six-month prevalence of psychiatric disorders in three communities. Archives of General Psychiatry, 41, 959–967.PubMedCrossRefGoogle Scholar
  16. Pariser, S.F., Pinta, E.R., & Jones, B.A. (1978). Mitral valve prolapse syndrome and anxiety neurosis/panic disorder. American Journal of Psychiatry, 135, 246–247.PubMedGoogle Scholar
  17. Rickels, K. (1978). Use of antianxiety agents in anxious outpatients. Psychopharmacology, 58, 1–17.PubMedCrossRefGoogle Scholar
  18. Rickels, K. (1983). Nonbenzodiazepine anxiolytics: Clinical usefulness. Journal of Clinical Psychiatry, 44, 38–43.PubMedGoogle Scholar
  19. Robins, L.N., Heizer, J.E., Weissman, M.M., Orvaschel, H., Gruenberg, E., Burke, J.D. Jr., & Regier, D.A. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry, 41, 949–958.PubMedCrossRefGoogle Scholar
  20. Saravay, S.M., Mark. J., Steinberg, M., & Rabiner, C. (1984). Lidocaine psychosis: A model for liaison research. Psychosomatic Medicine, Abstract: XLVI, 82.Google Scholar
  21. Sheehan, D., Ballenger, J., & Jacobsen, G. (1980). The treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51–59.PubMedCrossRefGoogle Scholar
  22. Sheehan, D.V., Claycomb, J.B., Surman, O.S., Gelles, L., Gallo, J., & LeGros, J. (1984). The relative efficacy of alprazolam, phenelzine, and imipramine in treating panic attacks and phobias. Paper presented to the 137th annual meeting, American Psychiatric Association, Los Angeles.Google Scholar
  23. Spitzer, R.L., & Williams, J.B.W. (1986). Proposed revision in the DSM-III classification of anxiety disorders based on research and clinical experience. In B.F. Shaw, Z.V. Segal, T.M. Vallis, & F.E. Cashman (Eds.), Anxiety disorders: Psychological and biological perspectives. New York: Plenum Press.Google Scholar
  24. Tyrer, P., Candy, J., & Kelly, D.A. (1973). A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia, 32, 237–254.PubMedCrossRefGoogle Scholar
  25. Venkatesh, A., Pauls, D.L., Crowe, R., Noyes, R. Jr., Van Valkenburg, C., Martins, J., & Kerber, R. (1978). Mitral valve prolapse in patients with anxiety neurosis. Clinical Research, 26, 656.Google Scholar
  26. Wolpe, J. (1969). The practice of behavior therapy. New York: Pergamon Press.Google Scholar
  27. Zitrin, C.M., & Juliano, M. (1984). Unpublished data.Google Scholar
  28. Zitrin, C.M., Klein, D.F., & Woerner, M.G. (1978). Behavior therapy, supportive psychotherapy, imipramine and phobia. Archives of General Psychiatry, 35, 307–316.PubMedCrossRefGoogle Scholar
  29. Zitrin, C.M., Klein, D.F., & Woerner, M.G. (1980). Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry, 37, 63–72.PubMedCrossRefGoogle Scholar
  30. Zitrin, C.M., Klein, D.F., Woerner, M.G., & Ross, D. (1983). Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry, 40, 125–138.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Charlotte M. Zitrin
    • 1
  1. 1.Long Island Jewish-Hillside Medical CenterUSA

Personalised recommendations